Adial Narrows Losses, Faces Going Concern Doubt Despite Capital Influx

TL;DR

**ADIL is burning cash and needs more, making it a high-risk bet on future AD04 success and further dilution.**

AI Summary

ADIAL PHARMACEUTICALS, INC. reported a net loss of $1,793,651 for the three months ended September 30, 2025, a decrease from the $2,191,803 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $5,981,008, significantly lower than the $11,126,661 loss in the prior year, primarily due to the absence of a $4,464,427 inducement expense incurred in 2024. Research and development expenses decreased by 49.5% to $521,069 for the three months ended September 30, 2025, from $1,031,633 in 2024, and by 19.9% to $2,000,275 for the nine months ended September 30, 2025, from $2,498,433 in 2024. The company's cash and cash equivalents increased to $4,606,289 as of September 30, 2025, from $3,750,525 at December 31, 2024, bolstered by $5,873,801 in net cash from financing activities, including $3,604,829 from common stock sales and $2,268,972 from warrant exercises. Despite these financing activities, the company explicitly states that existing cash is not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

Adial's continued net losses and explicit 'going concern' warning signal significant financial instability for investors, despite a reduction in R&D spending and recent capital raises. The company's reliance on future capital to fund AD04 development means existing shareholders face substantial dilution risk, as evidenced by the increase in common shares outstanding from 6,474,588 to 23,836,383 within nine months. For employees, this raises job security concerns, while customers and the broader market await the uncertain future of AD04, a potential addiction treatment, in a competitive pharmaceutical landscape. The company's ability to secure additional funding will dictate its survival and competitive positioning.

Risk Assessment

Risk Level: high — The company explicitly states, "the Company does not believe that the existing cash and cash equivalents are sufficient to fund operations for the next twelve months following the filing of these unaudited condensed consolidated financial statements." This, coupled with an accumulated deficit of $87,976,331 as of September 30, 2025, and a history of losses since inception, indicates a high risk of financial distress and reliance on future capital raises.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the explicit going concern warning and continuous need for capital, potential investors should wait for clear evidence of successful AD04 clinical trials, regulatory approval, and a robust financing plan that doesn't heavily dilute existing shareholders before considering a position.

Financial Highlights

total Assets

$5,659,847

total Debt

$1,154,756

net Income

-$5,981,008

eps

-$0.45

cash Position

$4,606,289

Key Numbers

• $1.79M — Net Loss (Q3 2025) (Decreased from $2.19M in Q3 2024, indicating a narrowing of losses.)
• $5.98M — Net Loss (9 months 2025) (Significantly lower than $11.13M in 9 months 2024, primarily due to absence of inducement expense.)
• $4.61M — Cash and Cash Equivalents (Increased from $3.75M at Dec 31, 2024, but still insufficient for 12 months of operations.)
• $5.87M — Net Cash from Financing (Raised through stock sales and warrant exercises, crucial for current liquidity.)
• 23.84M — Common Shares Outstanding (Increased from 6.47M at Dec 31, 2024, indicating significant shareholder dilution.)
• $2.00M — R&D Expenses (9 months 2025) (Decreased by 19.9% from $2.50M in 9 months 2024.)
• $87.98M — Accumulated Deficit (Increased from $81.99M at Dec 31, 2024, reflecting ongoing losses.)
• $0.08 — Loss per share (Q3 2025) (Improved from $0.38 in Q3 2024, partly due to increased share count.)

Key Players & Entities

• ADIAL PHARMACEUTICALS, INC. (company) — Registrant
• Purnovate, Inc. (company) — Wholly owned subsidiary
• Adovate, LLC (company) — Acquirer of Purnovate assets
• NASDAQ (regulator) — Exchange where Common Stock is registered
• SEC (regulator) — Securities and Exchange Commission
• $1,793,651 (dollar_amount) — Net Loss for Q3 2025
• $5,981,008 (dollar_amount) — Net Loss for nine months ended Sep 30, 2025
• $4,606,289 (dollar_amount) — Cash and cash equivalents as of Sep 30, 2025
• $5,873,801 (dollar_amount) — Net cash provided by financing activities for nine months ended Sep 30, 2025
• 23,836,383 (dollar_amount) — Common shares outstanding as of Sep 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company explicitly states that its existing cash and cash equivalents of $4,606,289 as of September 30, 2025, are not sufficient to fund operations for the next twelve months. This raises substantial doubt about its ability to continue as a going concern, despite an increase in cash from $3,750,525 at December 31, 2024.
• Significant Shareholder Dilution [high — financial]: The number of common shares outstanding has increased dramatically from 6,474,588 at December 31, 2024, to 23,836,383 at September 30, 2025. This nearly fourfold increase, driven by $5,873,801 in net cash from financing activities, indicates significant dilution for existing shareholders.
• Accumulated Deficit [medium — financial]: The company's accumulated deficit has grown to $87,976,331 as of September 30, 2025, an increase from $81,995,323 at December 31, 2024. This ongoing trend of increasing losses highlights the company's persistent unprofitability.
• Dependence on Equity Financing [medium — operational]: The company's liquidity is heavily reliant on net cash from financing activities, which totaled $5,873,801 for the nine months ended September 30, 2025. This dependence on external funding, particularly common stock sales ($3,604,829) and warrant exercises ($2,268,972), makes future operations vulnerable to market conditions and investor sentiment.
• Equity Method Investment Volatility [low — operational]: The company recorded a loss on its equity method investment in Adovate of $338,740 for the nine months ended September 30, 2025. The value and performance of this investment, which represents a significant asset ($643,090 as of September 30, 2025), introduce an element of financial risk.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Adial Pharmaceuticals operate in a competitive landscape where innovation and successful clinical trials are paramount. The sector is also subject to evolving reimbursement policies and market access challenges, impacting revenue generation and profitability.

Regulatory Implications

As a pharmaceutical company, Adial is subject to stringent regulations from bodies like the FDA. Failure to comply with these regulations, or delays in drug approval processes, can have severe financial and operational consequences. The company's financial condition also raises questions about its ability to fund ongoing compliance and development activities.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Evaluate the impact of R&D expense reduction.
3. Assess the dilution from equity issuances.
4. Scrutinize the equity method investment performance.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $1,793,651 and cash of $4,606,289, with explicit going concern warning.
• 2025-09-30: Common Shares Outstanding as of Q3 2025 — 23,836,383 shares, a significant increase from year-end 2024, indicating dilution.
• 2024-12-31: End of Fiscal Year 2024 — Reported cash of $3,750,525 and accumulated deficit of $81,995,323.
• 2024-09-30: End of Q3 2024 — Reported net loss of $2,191,803 and incurred a significant $4,464,427 inducement expense.

Glossary

Inducement expense

An expense incurred by a company to incentivize a party to enter into a transaction, often related to debt or equity offerings. (The absence of a $4,464,427 inducement expense incurred in the prior year significantly improved the net loss for the nine months ended September 30, 2025.)

Equity method investment

An accounting method used to report investments in which the investor has the ability to exercise significant influence over the investee's operating and financial policies. (Adial Pharmaceuticals has an equity method investment in Adovate, which contributed to losses and is recorded on the balance sheet.)

Going concern

The assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company explicitly states substantial doubt about its ability to continue as a going concern, a critical warning for investors.)

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. (The increasing accumulated deficit to $87,976,331 reflects the company's ongoing unprofitability.)

Warrant exercises

The process by which holders of warrants (options to buy stock at a specific price) convert them into actual shares of stock. (Warrant exercises contributed $2,268,972 to the company's financing activities, bolstering cash but also potentially increasing share count.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Adial Pharmaceuticals has narrowed its net loss from $2,191,803 to $1,793,651, and significantly reduced its nine-month net loss from $11,126,661 to $5,981,008, largely due to the absence of a substantial inducement expense in 2024. Research and development expenses have also seen a notable decrease. However, the company's cash position has improved to $4,606,289, but it remains insufficient for 12 months of operations, and the accumulated deficit has continued to grow, while common shares outstanding have dramatically increased, signaling significant dilution.

Filing Documents

• ea0263114-10q_adial.htm (10-Q) — 603KB
• ea026311401ex31-1_adial.htm (EX-31.1) — 10KB
• ea026311401ex31-2_adial.htm (EX-31.2) — 12KB
• ea026311401ex32-1_adial.htm (EX-32.1) — 4KB
• ea026311401ex32-2_adial.htm (EX-32.2) — 4KB
• 0001213900-25-109979.txt ( ) — 4043KB
• adil-20250930.xsd (EX-101.SCH) — 33KB
• adil-20250930_cal.xml (EX-101.CAL) — 28KB
• adil-20250930_def.xml (EX-101.DEF) — 178KB
• adil-20250930_lab.xml (EX-101.LAB) — 337KB
• adil-20250930_pre.xml (EX-101.PRE) — 191KB
• ea0263114-10q_adial_htm.xml (XML) — 441KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item l. Condensed Consolidated Unaudited Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 4 Notes to the Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

– OTHER INFORMATION

PART II – OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Condensed Consolidated Unaudited Financial

Item 1. Condensed Consolidated Unaudited Financial ADIAL PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, 2025 December 31, 2024 ASSETS Current Assets: Cash and cash equivalents $ 4,606,289 $ 3,750,525 Prepaid expenses and other current assets 407,543 308,239 Total Current Assets 5,013,832 4,058,764 Intangible assets, net 2,925 3,348 Equity method investment 643,090 981,830 Total Assets $ 5,659,847 $ 5,043,942 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 556,284 $ 250,130 Accounts payable, related party — 48,272 Accrued expenses 598,472 677,456 Total Current Liabilities 1,154,756 975,858 Total Liabilities $ 1,154,756 $ 975,858 Commitments and contingencies – see Note 7 Stockholders' Equity Preferred Stock, 5,000,000 shares authorized with a par value of $ 0.001 per share, 0 shares outstanding at September 30, 2025 and December 31, 2024 — — Common Stock, 100,000,000 shares authorized with a par value of $ 0.001 per share, 23,836,383 and 6,474,588 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 23,836 6,473 Additional paid in capital 92,457,586 86,056,934 Accumulated deficit ( 87,976,331 ) ( 81,995,323 ) Total Stockholders' Equity 4,505,091 4,068,084 Total Liabilities and Stockholders' Equity $ 5,659,847 $ 5,043,942 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 ADIAL PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Operating Expenses: Research and development expenses $ 521,069 $ 1,031,633 $ 2,000,275 $ 2,498,433 General and administrative expenses 1,243,009 1,179,841 3,913,808 3,845,293 Total Operating Expenses 1,764,078 2,211,474 5,91

financial statements

financial statements. 4 — EQUITY METHOD INVESTMENTS On June 30, 2023, Adovate issued to the Company a 19.9 % equity stake in Adovate as part of consideration owed upon the exercise of Adovate's option to purchase the business and assets of the Company's wholly owned subsidiary, Purnovate, Inc. Under the terms of the final asset purchase agreement, Adovate was obligated to protect the Company against dilution by issuing additional equity to the Company in Adovate as Adovate equity was sold to maintain the Company's 15 % equity stake until such time as Adovate had raised $ 4 million through equity sales, at which time the Company's equity stake would be adjusted to equal to 15 %. The Company determined the fair value of this equity to be $ 1,727,897 at time of issue, based on the price of cash sales by Adovate of the same class of equity to third parties around the same time as the date of issue. On January 30, 2024, the Company acknowledged that Adovate had raised $ 4 million and the Company's equity in Adovate was reduced to equal 15 % of Adovate's equity then outstanding. As a result, the Company recorded a reduction on the value of its equity stake of $ 283,268 . In accordance with ASC 810, the Company determined that Adovate does not qualify as a variable interest entity, nor does the Company have a controlling financial interest in Adovate. The Company has influence over, but does not control Adovate through its equity interest in Adovate. The Company has determined that the equity it owns is in-substance common stock. The Company is not the primary beneficiary as it does not have the power to direct the activities of Adovate that most significantly impact Adovate's economic performance. Accordingly, the Company does not consolidate the financial statements of Adovate with those of the Company. The Company recorded the initial investment in Adovate of $ 1,727,897 in "Equity method investments" on its consolidated balance sheet. Due to the timing and avail

View Full Filing

View this 10-Q filing on SEC EDGAR